Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
-
Published:2024-05
Issue:3
Volume:62
Page:334-338
-
ISSN:2212-5345
-
Container-title:Respiratory Investigation
-
language:en
-
Short-container-title:Respiratory Investigation
Author:
Inutsuka Yu,
Iwama Eiji,
Shiraishi Yoshimasa,
Yoneshima Yasuto,
Shibahara DaisukeORCID,
Tanaka Kentaro,
Okamoto Isamu
Reference30 articles.
1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009
2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
3. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol,2016
4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;Kobayashi;N Engl J Med,2005
5. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011